SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-016060
Filing Date
2024-04-26
Accepted
2024-04-26 08:30:26
Documents
16
Period of Report
2024-04-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41946
2 ex99-1.htm EX-99.1 24966
3 ex99-1_001.jpg GRAPHIC 7740
  Complete submission text file 0001493152-24-016060.txt   304549

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tvgn-20240426.xsd EX-101.SCH 3815
5 XBRL DEFINITION FILE tvgn-20240426_def.xml EX-101.DEF 26691
6 XBRL LABEL FILE tvgn-20240426_lab.xml EX-101.LAB 36844
7 XBRL PRESENTATION FILE tvgn-20240426_pre.xml EX-101.PRE 25315
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5977
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

IRS No.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41002 | Film No.: 24878982
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)